Prof. Stephen Chan is an experienced clinical oncologist based in Nottingham. He has a specialist interest in the treatment of breast and gynaecological cancers. He holds expertise and many years of experience in treating these conditions with chemotherapy and radiotherapy. He is a firm believer in personalised therapies for each of his patients.
Watch The Patient Journey here - The Journey
He is a world leader in his field and is renowned for his innovative cancer research into the understanding and treatment of cancer. He has presented his work nationally and internationally.
Over the last 25 years, he has played a pivotal role in the discovery and licensing of a number of new chemotherapy treatments as well as novel targeted therapies. He is the senior author for over 100 research papers in world-renowned scientific journals and book chapters on new cancer drug development.
Professor Chan leads The Nottingham Personalised Therapy Oncology Research Group, and the Breast & Gynaecological Clinical Trial Group at the Nottingham University Hospital. The group’s current interests include the development of new cancer genes and tests to select the best treatment for individual patients.
He is the Senior Author of two new publications in 2015 on a new Cancer Gene “HAGE”; and a new index “ the Nottingham Prognostic Response Index”. These are likely improve the treatment results of breast cancer with chemotherapy
Prof Chan qualified as a doctor at the Nottingham University Medical School and went on to focus his medical training in oncology through research and training at Oxford University. His cancer expertise was further heightened by his oncogenes research project at Cambridge MRC and the Imperial College London which allowed him a better, more influential understanding of the complex disease.
He is also a board member of the Maggie’s charity in Nottingham.